Showing results (471-480 of 548) with videos related to
Sort By:
Pageof 55
American Journal of Clinical Pathology|November 21, 2020
Laboratory Workup of Lymphoma in AdultsSteven H Kroft, Cordelia E Sever, Adam Bagg, et al.Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|September 16, 2015
Clinical and molecular epidemiology of human rhinovirus infections in patients with hematologic malignancySamantha E Jacobs, Daryl M Lamson, Rosemary Soave, et al.British Journal of Haematology|January 29, 2014
A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab eraPeter J Hosein, Jocelyn C Maragulia, Matthew P Salzberg, et al.The Lancet. Haematology|December 5, 2016
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 studyRichard R Furman, Herbert A Eradat, Christine G DiRienzo, et al.The American Journal of Pathology|June 7, 2011
Inhibiting TGF-β activity improves respiratory function in mdx miceCarol A Nelson, R Bridge Hunter, Lindsay A Quigley, et al.Clinical Lymphoma, Myeloma & Leukemia|January 23, 2016
Role of Surveillance Imaging in Patients With Peripheral T-Cell LymphomaTiffany Tang, Zhengming Chen, Pannee Praditsuktavorn, et al.Cancer Medicine|February 17, 2023
Is local review of positron emission tomography scans sufficient in diffuse large B-cell lymphoma clinical trials? A CALGB 50303 analysisPallawi Torka, Levi D Pederson, Michael V Knopp, et al.Leukemia & Lymphoma|May 27, 2020
Potential impact of consolidation radiation therapy for advanced Hodgkin lymphoma: a secondary analysis of SWOG S0816Chul S Ha, Michael LeBlanc, Heiko Schöder, et al.Blood Advances|March 3, 2025
Nivolumab plus relatlimab in patients with relapsed or progressed B-cell malignancies in RELATIVITY-022Ajay K Gopal, Philippe Armand, Sattva S Neelapu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2018
Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016Mazyar Shadman, Hongli Li, Lisa Rimsza, et al.Pageof 55